News and Trends 2 May 2023 Cabaletta Bio’s lupus drug cleared for trial Cabaletta Bio, Inc., a U.S. clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to CABA-201. Cabaletta Bio’s CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, designed […] May 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by PL BioScience 25 Apr 2023 Becoming human: GMP-compliant supplements for cell therapy April 25, 2023 - 5 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
Sponsored by Business France 20 Apr 2023 8 life science innovators you must meet at BioTrinity 2023 April 20, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity Aspect Biosystems and Novo Nordisk A/S are set to collaborate on developing bioprinted tissue therapeutics to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s background in stem cell differentiation […] April 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2023 Could new riboswitch make gene therapy safer? Turning genes on and off as easily and predictably as flicking a switch could be a powerful tool in medicine and biotech. A type of technology called a riboswitch might be the key.The Okinawa Institute of Science and Technology (OIST) in Japan, in collaboration with Astellas Pharma Inc., has developed a new toolkit that uses […] March 30, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 LIfT BioSciences hails breakthrough data for treating solid tumors LIfT BioSciences has announced what it says are exciting preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities. The company said these are commonly cited by medical professionals as being critical for potentially curing solid tumors in patients. LIfT BioSciences said this involved learning from the experience of other […] March 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 8 Mar 2023 Phacilitate’s Women in Advanced Therapies program supports women in science Marlin Frechette is the chief quality and compliance officer at FUJIFILM Irvine Scientific. But she has another role. Frechette is also a member of Phacilitate’s Women in Advanced Therapies program, and was formerly a mentor, and she tells us here how the program supports women in executive level life science roles. Frechette takes up the […] March 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2023Beyond Biotech podcast 36: Bio-Europe Spring and Cellular Origins Two of the interviews on the podcast today are related to Bio-Europe Spring. There are conversations with Rosie Bernard, senior director, production and content strategy for EBD Group EU, with an overview of the event, and also Jordan Stillman, project manager, partnering services at EBD Group. We also have a chat with Cellular Origins’ CEO […] March 3, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2023 Porton and DanausGT look to boost development of gene and cell therapy Porton Advanced Solutions Ltd. and DanausGT Biotechnology Co., Ltd. have announced a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics. As an end-to-end gene and cell therapy service provider, Porton Advanced CDMO offers solutions covering plasmids, cell therapy, gene therapy, oncolytic viruses, mRNA therapy, and bacterial therapy. DanausGT […] March 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Syena created to deliver first-in-class TCR-NK cell therapy Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, have launched Syena, a new oncology-focused product company pioneering T-cell receptor (TCR) natural killer (NK) cell therapies (TCR-NKs). Building on the intellectual property and technology from MD Anderson and Replay, Syena has the […] February 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023 Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated four-week data on the patient, who lives with advanced heart failure and has given approval for […] February 10, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023 Cell and Gene Therapy Catapult boost for life science campus The Cell and Gene Therapy Catapult (CGT Catapult), an independent U.K. innovation and technology organization specializing in the advancement of cell and gene therapies, has announced its involvement in the development of a major new campus for life science businesses in Stevenage. The new campus was announced by UBS Asset Management’s Real Estate & Private […] February 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email